A case report: Treating insomnia with olanzapine in cancer patients
A low dose of olanzapine has potential to treat insomnia in cancer patients. The ideal dosing regimens and potential risks are unclear, especially for long-term use. More research and clinical trials are needed to evaluate off-label use of olanzapine for insomnia, including its efficacy and risks, and to optimize the dosage to reduce its side effects in cancer patients. Oncology providers should consider olanzapine as a potential treatment for insomnia, especially given its off-label uses and potential benefits.
Authors
- Kimberson Tanco (ORCID: https://orcid.org/0000-0002-2845-195X)
- Kenneth E. Warner (ORCID: https://orcid.org/0000-0002-8214-1776)
- Zhu Wang (ORCID: https://orcid.org/0000-0001-5122-7799)
- Eric Liu (ORCID: https://orcid.org/0000-0003-2286-0856)
- Sahithi Madireddy (ORCID: https://orcid.org/0000-0001-5522-0949)
- Thomas J. Smith (ORCID: https://orcid.org/0000-0003-3040-6434)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Johns Hopkins Hospital (US)
Publication Details
- Journal
- Palliative & Supportive Care
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/s1478951525100345
- Citations
- 2
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94